BB Biotech Q3 net profit falls as NAV trails biotech index
Swiss investment firm BB Biotech reported lower quarterly net profit, and its net asset value underperformed the biotech index, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Swiss investment firm BB Biotech's third-quarter net profit declined year over year, while its net asset value (NAV) lagged the biotech index. Net income came in at CHF 175 million.
During the quarter, three portfolio companies won US drug approvals, and CHF 280 million from two M&A transactions was reinvested into twelve new positions. The company exited eight positions and rebuilt some holdings at lower valuations.
BB Biotech expects further clinical and regulatory milestones in the fourth quarter and sees selective opportunities in shares that fell without a change to clinical prospects. The company says sustained NAV performance versus its benchmark remains its key measure. Per LSEG data, the average analyst rating is buy, and the stock trades at about 35 times forward earnings, up from 23 three months earlier.
why it matters
The results matter for biotech investors because they show how large funds value drugs approaching regulatory decisions and how deal proceeds are redeployed. The NAV gap versus the index and the higher multiple may affect investor interest in the shares.
market impact
Biotech funds: NAV lagging the index may weigh on investor interest in BB Biotech shares
tags
instruments
sources
- BB Biotech Q3 net profit falls, NAV underperforms biotech index — Reuters, 23 October 2026 at 05:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗